Related Experiment Video
Updated: Aug 5, 2026
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Prognostic factors in paediatric-onset multiple sclerosis: a narrative review
Mariaclara Achille1, Massimiliano Copetti2, Tommaso Guerra1
1Department of Translational Biomedicine and Neurosciences (DiBraiN), University of Bari "Aldo Moro", Bari, Italy.
Insights
Predicting disability in pediatric-onset multiple sclerosis (POMS) requires distinguishing prognostic factors from susceptibility ones. Early inflammatory activity and MRI findings are key predictors, but a validated prognostic score is still needed.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Paediatric-onset multiple sclerosis (POMS) is distinct from adult MS, necessitating specific risk stratification.
- Current literature often conflates susceptibility, conversion, and prognosis in POMS.
- Accurate prognosis is crucial for managing long-term outcomes in children with MS.
Purpose of the Study:
- To provide a narrative overview of candidate prognostic factors in POMS.
- To differentiate prognostic factors from those related to susceptibility and conversion.
- To organize identified factors by the specific outcome they predict.
Main Methods:
- Searched PubMed and Google Scholar (2002-2025, with hand searching of pivotal 2026 cohorts).
- Classified factors along three axes of inference and graded evidence into four tiers.
- No formal risk-of-bias assessment was conducted due to the narrative design.
Main Results:
- Early inflammatory activity (relapses, interval, annualized relapse rate, EDSS change) and lesion topography (brainstem, spinal cord) are reproducible predictors.
- T2 lesion accrual, serum neurofilament light chain, and treatment variables (delayed DMT, early high-efficacy treatment) also show predictive value.
- Advanced MRI metrics and some fluid biomarkers are preliminary; baseline EDSS was inconsistent. Dietary/environmental factors relate to susceptibility, not prognosis.
Conclusions:
- Current evidence identifies candidate predictors but lacks a validated prognostic instrument for POMS.
- Confounding by indication complicates inference.
- A multidimensional, externally validated POMS-specific prognostic score is yet to be developed.
Background:
Paediatric-onset multiple sclerosis (POMS) accounts for 3-10% of multiple sclerosis (MS) cases and differs from adult-onset disease in course, treatment response and long-term outcomes. Risk stratification is essential, yet the literature frequently conflates three distinct questions: which children develop MS (susceptibility), which convert from a first demyelinating event (conversion) and which, once diagnosed, will accrue disability (prognosis).
Objective:
This study aimed to provide a narrative overview of candidate prognostic factors in POMS, separated from susceptibility and conversion factors and organised by the outcome each predicts.
Methods:
PubMed and Google Scholar were searched (2002-2025, with hand searching of pivotal 2026 cohorts) using a predefined string and full eligibility criteria. Factors were classified along three axes of inference and graded into four evidence tiers (replicated; preliminary; susceptibility rather than prognosis; inconsistent). No formal risk-of-bias assessment was undertaken, consistent with the narrative design.
Results:
The most reproducible post-diagnosis predictors were early inflammatory activity (relapse number and inter-attack interval in the first two years, annualised relapse rate, early EDSS change), lesion topography (brainstem, spinal cord), T2 lesion accrual, serum neurofilament light chain and treatment-related variables (delayed disease-modifying therapy, early high-efficacy treatment). Advanced MRI metrics, serum glial fibrillary acidic protein and other fluid biomarkers remain preliminary; baseline EDSS was inconsistent. Most dietary, environmental and perinatal exposures relate to susceptibility, not course.
Conclusions:
Current evidence supports candidate predictors, not a validated instrument, and inference is further complicated by confounding by indication. A multidimensional, externally validated POMS-specific prognostic score remains to be developed-the aim of the ongoing PROMISING study.
